Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
23 Dec 2020
Historique:
received: 30 11 2020
revised: 17 12 2020
accepted: 21 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 10 4 2021
Statut: epublish

Résumé

The purpose of this study is to develop peptide-based platelet-derived growth factor receptor

Identifiants

pubmed: 33374773
pii: molecules26010041
doi: 10.3390/molecules26010041
pmc: PMC7795354
pii:
doi:

Substances chimiques

Gallium Radioisotopes 0
Peptide Fragments 0
Radiopharmaceuticals 0
Gallium-67 4LJK511Z86
PDGFRB protein, human EC 2.7.10.1
Receptor, Platelet-Derived Growth Factor beta EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Nucl Med Biol. 2015 Nov;42(11):816-23
pubmed: 26302836
Adv Cancer Res. 2007;97:247-74
pubmed: 17419949
PLoS One. 2013 Dec 31;8(12):e84335
pubmed: 24391942
Mol Imaging Biol. 2013 Apr;15(2):212-21
pubmed: 22791264
J Am Chem Soc. 2002 Dec 18;124(50):14922-33
pubmed: 12475334
Mol Pharm. 2014 Nov 3;11(11):3957-64
pubmed: 24972112
Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86
pubmed: 15207817
J Control Release. 2019 Mar 28;298:194-201
pubmed: 30763622
J Biol Chem. 2003 Dec 5;278(49):49582-8
pubmed: 14506245
Mol Cell Biol. 2000 Nov;20(22):8352-63
pubmed: 11046132
Bioconjug Chem. 2008 Feb;19(2):539-47
pubmed: 18197608
Bioorg Med Chem. 2017 Oct 15;25(20):5576-5585
pubmed: 28838832
Bioconjug Chem. 2008 Sep;19(9):1803-12
pubmed: 18712899
Nucl Med Biol. 2013 Feb;40(2):197-205
pubmed: 23218795
Bioconjug Chem. 2009 Dec;20(12):2199-213
pubmed: 19719118
Nucl Med Biol. 2006 May;33(4):513-20
pubmed: 16720243
Theranostics. 2012;2(5):481-501
pubmed: 22737187
Protein Cell. 2019 Nov;10(11):787-807
pubmed: 31140150
J Nucl Med. 2014 Feb;55(2):294-300
pubmed: 24408895
Mol Pharm. 2014 Nov 3;11(11):3938-46
pubmed: 25054774
PLoS One. 2013 Aug 01;8(8):e70028
pubmed: 23936372
Curr Top Med Chem. 2010;10(12):1227-36
pubmed: 20388106
Sci Rep. 2017 Oct 25;7(1):13971
pubmed: 29070853
Sci Rep. 2018 Jul 10;8(1):10369
pubmed: 29991770
J Biol Chem. 1993 Feb 15;268(5):3625-31
pubmed: 7679113
Chem Pharm Bull (Tokyo). 2018;66(6):651-659
pubmed: 29863067
Nucl Med Biol. 2010 Oct;37(7):751-61
pubmed: 20870150
Nucl Med Biol. 2013 May;40(4):445-50
pubmed: 23528561
Chem Pharm Bull (Tokyo). 2020;68(6):538-545
pubmed: 32475858
Theranostics. 2011 Jan 18;1:58-82
pubmed: 21547153
Adv Drug Deliv Rev. 2017 Feb;110-111:38-51
pubmed: 27327937
Breast Cancer Res Treat. 2018 Jun;169(2):231-241
pubmed: 29380207
Mol Ther. 2014 Apr;22(4):828-41
pubmed: 24566984
ACS Med Chem Lett. 2013 Jan 1;4(1):98-102
pubmed: 23524643
Bioorg Med Chem. 2019 Jan 15;27(2):383-393
pubmed: 30563725
Oncol Rep. 2018 May;39(5):2178-2184
pubmed: 29498405
Bioconjug Chem. 2009 May 20;20(5):856-67
pubmed: 19344122
Ann Nucl Med. 2019 Apr;33(4):244-251
pubmed: 30604401
Mol Pharm. 2009 Jan-Feb;6(1):231-45
pubmed: 19067525
Science. 1995 Mar 24;267(5205):1782-8
pubmed: 7892601
World J Surg. 2016 Aug;40(8):1977-84
pubmed: 26940582
Nucl Med Biol. 2011 Jul;38(5):631-6
pubmed: 21718937
Molecules. 2017 Aug 02;22(8):
pubmed: 28767081
Mol Imaging Biol. 2013 Aug;15(4):391-400
pubmed: 23381728
J Nucl Med. 2011 Mar;52(3):470-7
pubmed: 21321264
J Nucl Med. 2003 May;44(5):823-31
pubmed: 12732685
Bioconjug Chem. 2015 Aug 19;26(8):1561-70
pubmed: 26087328
Mol Pharm. 2017 Feb 6;14(2):523-532
pubmed: 28094532

Auteurs

Nurmaya Effendi (N)

Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Faculty of Pharmacy, Universitas Muslim Indonesia, Urip Sumiharjo KM. 10, Makassar 90-231, Indonesia.

Kenji Mishiro (K)

Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Kazuhiro Shiba (K)

Advanced Science Research Center, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8640, Japan.

Seigo Kinuya (S)

Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan.

Kazuma Ogawa (K)

Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH